住院患者上肢深静脉血栓的患病率与临床结局
单中心回顾性研究纳入2016年1月至2018年2月住院的63045例患者,1000例(1.6%)诊断上肢深静脉血栓(UE-DVT)。住院期间死亡12.1%但与UE-DVT无关,大出血47.6%,肺栓塞4.8%,复发性UE-DVT 6.1%。
要点
- 住院患者UE-DVT患病率1.6%,静脉双功超声阳性率27.0%。
- 大多数患者诊断时已接受预防或抗凝,仍发生UE-DVT。
- 静脉装置增加肺栓塞和复发性UE-DVT风险。
核心结论
- UE-DVT是住院患者常见并发症(1.6%),急性肺栓塞、复发性DVT和出血仍是重要并发症。
- 标准血栓预防是否有效预防UE-DVT尚不明确,需更多研究指导预防和治疗。
研究设计与样本
- 回顾性单中心研究,纳入2016年1月至2018年2月(26个月)住院且年龄≥18岁、上肢双功超声诊断为急性UE-DVT的患者。
- 共63045例住院患者中1000例(1.6%)诊断UE-DVT;期间3695次上肢静脉双功超声检查中27.0%为急性UE-DVT阳性。
主要发现
- 平均年龄55.0±17.2岁,男性58.3%,白人49.2%,平均体重指数29.4±10.3 kg/m2。
- 最常受累静脉为右颈内静脉(54.8%);96.9%诊断时已接受静脉血栓栓塞预防或抗凝治疗;77.8%诊断时留置静脉装置。
- 84.4%住院期间接受抗凝治疗,仅54.5%出院时带抗凝治疗。
- 住院期间死亡12.1%但与UE-DVT无关,大出血47.6%(致命性出血1%),肺栓塞4.8%(致命性0.7%),复发性UE-DVT 6.1%。
- 多因素分析显示高龄、癌症、重症监护室入住、合并下肢DVT和UE-DVT诊断前出血增加死亡风险;静脉装置增加肺栓塞和复发性UE-DVT风险;静脉装置、女性和合并下肢DVT增加大出血风险。
临床怎么用
- 住院患者出现上肢症状时应考虑UE-DVT可能,尤其有静脉装置者。
- UE-DVT患者住院期间抗凝治疗常见,但出院时抗凝治疗比例仅约一半,需关注治疗延续性。
- 合并静脉装置、女性或下肢DVT的UE-DVT患者应警惕大出血风险。
局限性
- 回顾性单中心研究,结果外推需谨慎。
- 原文未报告预防措施的具体方案和抗凝药物细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Upper extremity (UE) deep vein thrombosis (DVT) is a common and increasing complication in hospitalized patients. The objective of the present study was to determine the prevalence, treatment strategies, complications, and outcomes of UE-DVT. METHODS: We performed a retrospective single-institution study of patients with a diagnosis of UE-DVT from January 2016 through February 2018 (26 months). Patients aged ≥18 years who had been admitted to the hospital and who had had positive UE duplex ultrasound findings for acute UE-DVT were included in the present study. The outcomes were in-hospital mortality, major bleeding, pulmonary embolism (PE), and recurrent UE-DVT. RESULTS: Among 63,045 patients admitted to the hospital, 1000 (1.6%) had been diagnosed with UE-DVT. Of 3695 UE venous duplex ultrasound examinations performed during the study period, almost one third (27.0%) were positive for acute UE-DVT. The mean age was 55.0 ± 17.2 years, and most patients were men (58.3%), white (49.2%), and overweight (mean body mass index, 29.4 ± 10.3 kg/m2). The most affected vein was the right internal jugular vein (54.8%). Most of the patients (96.9%) has been receiving venous thromboembolism prophylaxis or anticoagulation therapy at the diagnosis. Most patients (77.8%) had had an intravenous device (IVD) in place at the diagnosis. Most of the patients (84.4%) were treated with anticoagulation therapy in the hospital but only one half (54.5%) were discharged with anticoagulation therapy. In-hospital mortality was 12.1% unrelated to UE-DVT, major bleeding occurred in 47.6% of the patients during hospitalization (fatal bleeding, 1%), PE was diagnosed in 4.8% of the patients, and 0.7% were fatal. Recurrent UE-DVT occurred in 6.1% of the patients. On multivariable analysis, the risk of death was increased by older age, cancer, intensive care unit admission, concomitant lower extremity DVT, and bleeding before the UE-DVT diagnosis. The presence of an IVD increased the risk of PE and the risk of recurrent UE-DVT. The risk of major bleeding was increased by the presence of an IVD, female sex, and concomitant lower extremity DVT. CONCLUSIONS: UE-DVT is a common complication in hospitalized patients (1.6%). Consequent acute PE and recurrent DVT remain important complications, as does bleeding. It is unclear whether standard thromboprophylaxis effectively protects against UE-DVT. More studies dedicated to UE-DVT are required to provide appropriate guidance on prophylaxis and treatment.
引用
- Cires-Drouet RS, Durham F, Sharma J, et al. Prevalence and clinical outcomes of hospitalized patients with upper extremity deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34089941. doi:10.1016/j.jvsv.2021.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。